If you’ve been diagnosed with an advanced solid tumor, you know how important it is to find the right treatment as quickly as possible. A newer type of cancer test called a liquid biopsy can now help your doctor identify the most effective therapies using nothing more than a simple blood draw. Thanks to a recent Medicare coverage decision for a comprehensive genomic profiling test called PanTracer LBx, this advanced diagnostic option is now more accessible and affordable for seniors across the country.
What Is a Liquid Biopsy?
A liquid biopsy is a blood test that analyzes your cancer’s genetic makeup without requiring surgery or a tissue sample. Traditional biopsies often involve invasive procedures where a doctor removes a small piece of a tumor for lab testing. While tissue biopsies remain valuable, they aren’t always possible. Some tumors are hard to reach, and some patients aren’t healthy enough for an invasive procedure. That’s where liquid biopsy steps in as a less burdensome alternative.
When cancer cells break down, they release tiny fragments of DNA into your bloodstream. These fragments are known as circulating tumor DNA, or ctDNA. A liquid biopsy captures and analyzes these fragments to build a detailed genetic profile of your cancer. This profile reveals specific mutations and biomarkers that can help your oncologist determine which treatments are most likely to work for you. It’s a powerful diagnostic tool that transforms a routine blood draw into a clear window into your cancer’s biology, giving your care team the molecular-level insight they need to act quickly and precisely.
How PanTracer LBx Works
NeoGenomics, a leading cancer diagnostics company, developed the PanTracer LBx test specifically for patients with advanced solid tumors. The test evaluates more than 500 genes from a single blood sample, including important biomarkers like microsatellite instability (MSI) and blood-based tumor mutational burden (bTMB). These markers help your doctor understand how your cancer behaves at the molecular level and which targeted therapies or immunotherapies might be most effective for your particular case.
One of the biggest advantages of PanTracer LBx is its turnaround time. Results are typically available within seven days, which means you and your doctor won’t have to wait weeks before making treatment decisions. The test can be ordered on its own, used as a backup when a tissue biopsy doesn’t yield enough material, or run alongside tissue testing to give your care team a more complete picture. This flexibility is especially helpful if you’re being treated at a community oncology practice, where access to tissue-based comprehensive genomic profiling can sometimes be more limited than at a large academic medical center.
What Medicare Coverage Means
On March 16, 2026, NeoGenomics announced that PanTracer LBx received coverage through the Centers for Medicare and Medicaid Services’ Molecular Diagnostics Services Program, known as MolDX. This means that if you’re a Medicare beneficiary, the cost of this test can now be covered under your plan. Before this decision, many seniors faced significant out-of-pocket expenses for comprehensive genomic profiling through liquid biopsy. That financial burden made it harder for some patients to access these advanced cancer diagnostics when they needed them most.
Medicare coverage removes one of the largest barriers between you and precision cancer care. You shouldn’t have to choose between your financial well-being and getting the most advanced diagnostic testing available. With this coverage in place, your oncologist can order PanTracer LBx with the confidence that Medicare will help cover the cost. This is particularly meaningful if you’re receiving treatment in a community setting rather than a major cancer center, since community oncology practices treat a significant share of Medicare-age cancer patients across the United States.
It’s also worth knowing that this coverage decision applies broadly to Medicare patients with advanced solid tumors. You don’t need a specific type of cancer to qualify. Whether you’re dealing with lung cancer, breast cancer, colorectal cancer, or another solid tumor, you may be eligible for this covered testing. Your oncologist can help you determine whether liquid biopsy is clinically appropriate based on your diagnosis and treatment history.
Why Early Genomic Testing Matters
If you’ve recently been diagnosed with advanced cancer, time is critical. The sooner your doctor understands your cancer’s genetic profile, the sooner you can begin a treatment approach that’s designed to target your specific disease. Genomic testing like PanTracer LBx can identify mutations that respond to targeted therapies. These are drugs engineered to attack cancer cells carrying specific genetic changes while leaving healthy cells largely unharmed. Without genomic profiling, your treatment plan might rely on broader approaches like standard chemotherapy, which, while still an important part of cancer care, doesn’t offer the same level of precision.
Targeted therapies and immunotherapies have dramatically improved outcomes for many patients whose cancers carry identifiable mutations. Genomic testing helps your doctor match you with these newer and often more effective options. In some cases, your results may also reveal that you’re eligible for clinical trials studying next-generation treatments you wouldn’t otherwise have known about. These trials can open doors to therapies that aren’t yet widely available, potentially giving you access to the most current advances in cancer medicine.
There’s another practical benefit to liquid biopsy that’s easy to overlook. Because it only requires a blood draw, you can have it done at your doctor’s office or a local lab. You won’t need to schedule a surgical procedure, recover from anesthesia, or manage the discomfort and risks associated with a traditional tissue biopsy. For many seniors who are already managing other health conditions, this simpler and less invasive approach can make a meaningful difference in your day-to-day experience during cancer treatment. It’s one less physical burden at a time when your energy and comfort matter more than ever.
Talking to Your Doctor
If you think liquid biopsy testing could benefit you, the most important step is to bring it up with your oncologist. Ask whether comprehensive genomic profiling could help shape your treatment plan. Let your doctor know you’ve learned about PanTracer LBx and that it’s now covered by Medicare for patients with advanced solid tumors. From there, your oncologist can evaluate whether the test makes sense given your diagnosis, your treatment history, and your current overall health.
You should also feel comfortable asking questions about what the results will show and how they’ll influence your care. Genomic profiling reports can be detailed and complex, but your care team is there to explain the findings in terms you can understand. Knowing which mutations or biomarkers your cancer carries, and what treatment pathways those results open up, can give you a much greater sense of involvement and control over your own care. If you’d like a deeper explanation, don’t hesitate to ask for a referral to a genetic counselor who specializes in oncology.
It’s also a good idea to verify coverage specifics with your Medicare plan before the test is ordered. While PanTracer LBx now has MolDX coverage, the details of your individual plan and any supplemental insurance you carry may affect what you owe. A quick phone call to your insurance provider can help you understand what to expect financially so there aren’t any surprises when the bill arrives.
Conclusion
The approval of Medicare coverage for PanTracer LBx is an important step forward in making advanced cancer diagnostics available to more seniors. You now have access to a comprehensive, noninvasive genomic test that can help your oncologist pinpoint the most effective treatments for your specific cancer. With results available in as little as seven days from a straightforward blood draw, liquid biopsy testing offers both speed and convenience during a time when every day counts.
If you’re living with advanced cancer or supporting a loved one through treatment, it’s worth exploring whether liquid biopsy could play a role in your care. Talk to your doctor, ask about genomic profiling options like PanTracer LBx, and take advantage of the Medicare coverage that’s now in place. For more information about Medicare-covered liquid biopsy testing, please call 866-633-4427 to speak with a Senior Healthcare Solutions Medicare expert.
